3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
4
Depression
2
Anxiety Disorders
2
Stress Disorders, Post-Traumatic
1
Motor Activity
1
Mental Fatigue
1
Fatigue
1
Death
1
Cognitive Dysfunction
1
Breast Neoplasms
1
Advanced Cancer
1
Interventions
Nivolumab
20
Ipilimumab
10
Paclitaxel
7
linrodostat
6
Standard of Care
6
Sirolimus
5
Gemcitabine
5
Bevacizumab
5
temsirolimus
4
relatlimab
4
Pemetrexed
4
Docetaxel
4
Carboplatin
4
ARRY-334543
4
Vorinostat
3
Erlotinib Hydrochloride
3
Dasatinib
3
Cetuximab
3
regorafenib
2
olaparib
2
apatinib
2
anlotinib
2
abemaciclib
2
Trastuzumab
2
Surveys and Questionnaires
2
Sunitinib
2
Sorafenib
2
Olanzapine
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Cancer
×
Coping Skills
×
Clear all
NCT01444157
2014-07-18
FamCope
Bispebjerg Hospital
Phase 3
Completed
700 enrolled